ADVA
13.5.2020 09:02:19 CEST | Business Wire | Press release
ADVA (FSE: ADV) and 6WIND today announced that German telecommunication carrier WiTCOM is using ADVA’s Ensemble Connector and 6WIND’s Turbo IPsec vRouter as key components of its new edge cloud platform. The open multi-vendor solution enables WiTCOM to power its smart city initiative with network functions virtualization (NFV) and universal customer premises equipment (uCPE). Built on best-of-breed technology from five leading suppliers, the solution supports the rapid and efficient rollout of IoT, video and next-generation services across WiTCOM’s IPv6 network and enables easy scalability for global deployments. Other partners in the project are Advantech, dacoso and Dell Technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005054/en/
“We took an innovative approach for an open multi-vendor solution to power our smart city initiative working with 6WIND, ADVA, Advantech, Dell Technologies and dacoso,” said Volker Bodenbach, head of technology and operations, WiTCOM. “Together we designed a secure open platform that powers edge cloud for IoT, video and next-generation services across our IPv6 network that can further be deployed worldwide across many verticals.”
WiTCOM’s new multi-vendor platform is composed of technologies optimized for edge cloud architecture. The uCPE approach brings dramatically increased efficiency and scale to the ICT service provider’s business. It also ensures that its customers benefit from ultimate choice and flexibility. Now, WiTCOM can streamline multiple virtual network functions (VNFs) on a single installation deployed close to the end customer, helping cities to digitalize their infrastructure and take advantage of the latest innovation in areas such as traffic control, surveillance and IoT.
“Our Ensemble Connector is the ideal solution for hosting and managing demanding uCPE applications. It’s now giving WiTCOM the power of the cloud along with several other benefits, such as zero-touch provisioning and platform security. It also provides access to the Ensemble Harmony ecosystem, which includes a wide variety of onboarded commercial VNFs,” commented James Buchanan, general manager, Edge Cloud, ADVA. “With its new uCPE network, WiTCOM can respond in an instant to customer demands and empower municipal networks to test out offerings and ideas. It will help accelerate the fourth industrial revolution and be a key tool in transforming cities into safer, less wasteful and more pleasant places to live.”
“6WIND’s vRouters provide the high-performance virtual routing foundation required for secure, scalable uCPE solutions,” said Eric Carmès, founder and CEO, 6WIND. “We are proud to work with WiTCOM alongside our partners ADVA, Advantech, dacoso and Dell Technologies to create an industry-leading smart city initiative for IoT, video and additional services.”
“Our task was to combine the components for this managed edge cloud solution into a finely tuned overall solution,” explained Karsten Geise, head of business and development, dacoso. “IoT via IPv6 public networks will be of great interest to many companies in the future if it meets such high security and automation requirements.”
“WiTCOM’s smart city blueprint extends the cloud infrastructure to the IoT edge, building a solid and open foundation to run innovative mobility and security services,” said James Yang, VP, Cloud-IoT Group, Advantech. “Our white box uCPE solutions help service providers like WiTCOM enable this intelligent edge with optimized platforms that provide ample computing power and rich connectivity while meeting edge environmental and mechanical constraints.”
Further information is available in this case study: https://adva.li/witcom-case-study .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005054/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom